Immunovirological studies of fatal infectious mononucleosis in a patient with X-linked lymphoproliferative syndrome treated with intravenous immunoglobulin and interferon-α

Motohiko Okano, Samuel Jay Pirruccello, Helen L. Grierson, Donald R. Johnson, Geoffrey Milton Thiele, David T. Purtilo

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

We have studied a 19-year-old male with X-linked lymphoproliferative syndrome (XLP) and infectious mononucleosis (IM) who was treated with high-dose immunoglobulin (500 mg/kg/day) and recombinant interferon (IFN)-α (2 × 106 IU/m2/day). Fulminant hepatitis was delayed; however, virus-associated hemophagocytic syndrome, cholestatic jaundice, and renal failure occurred terminally. Initially, nonspecific natural killer (NK) cell activity against K562 cells was normal but it gradually decreased. Although reactive T cells were markedly increased in his blood during the acute phase, spontaneous EBV-positive cell lines were easily established. Additionally, his mononuclear cells produced IFN-γ but not IFN-α prior to treatment. Based on results of in vitro studies, we conclude that both IFN-α and IFN-γ production are likely necessary for inhibiting EBV immortalization in vitro. Both IFN-α and -γ were produced in cultures of B95-8 EBV-infected mononuclear cells from EBV-seropositive healthy individuals. These results suggest that defective EBV-specific cytotoxic T cell activity accompanied with defective or discordant IFN-α and -γ production permitted the development of fatal IM in this patient. Combined treatment with immunoglobulin and IFN-α appeared to be partially effective during the early stage of this disease.

Original languageEnglish (US)
Pages (from-to)410-418
Number of pages9
JournalClinical Immunology and Immunopathology
Volume54
Issue number3
DOIs
StatePublished - Mar 1990

Fingerprint

Infectious Mononucleosis
Lymphoproliferative Disorders
Intravenous Immunoglobulins
Interferons
Human Herpesvirus 4
Immunoglobulins
T-Lymphocytes
Hemophagocytic Lymphohistiocytosis
K562 Cells
Obstructive Jaundice
Natural Killer Cells
Hepatitis
Renal Insufficiency
Viruses
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pathology and Forensic Medicine
  • Immunology

Cite this

@article{9017e1fbb51744f6aa310e9444d7f94c,
title = "Immunovirological studies of fatal infectious mononucleosis in a patient with X-linked lymphoproliferative syndrome treated with intravenous immunoglobulin and interferon-α",
abstract = "We have studied a 19-year-old male with X-linked lymphoproliferative syndrome (XLP) and infectious mononucleosis (IM) who was treated with high-dose immunoglobulin (500 mg/kg/day) and recombinant interferon (IFN)-α (2 × 106 IU/m2/day). Fulminant hepatitis was delayed; however, virus-associated hemophagocytic syndrome, cholestatic jaundice, and renal failure occurred terminally. Initially, nonspecific natural killer (NK) cell activity against K562 cells was normal but it gradually decreased. Although reactive T cells were markedly increased in his blood during the acute phase, spontaneous EBV-positive cell lines were easily established. Additionally, his mononuclear cells produced IFN-γ but not IFN-α prior to treatment. Based on results of in vitro studies, we conclude that both IFN-α and IFN-γ production are likely necessary for inhibiting EBV immortalization in vitro. Both IFN-α and -γ were produced in cultures of B95-8 EBV-infected mononuclear cells from EBV-seropositive healthy individuals. These results suggest that defective EBV-specific cytotoxic T cell activity accompanied with defective or discordant IFN-α and -γ production permitted the development of fatal IM in this patient. Combined treatment with immunoglobulin and IFN-α appeared to be partially effective during the early stage of this disease.",
author = "Motohiko Okano and Pirruccello, {Samuel Jay} and Grierson, {Helen L.} and Johnson, {Donald R.} and Thiele, {Geoffrey Milton} and Purtilo, {David T.}",
year = "1990",
month = "3",
doi = "10.1016/0090-1229(90)90054-T",
language = "English (US)",
volume = "54",
pages = "410--418",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Immunovirological studies of fatal infectious mononucleosis in a patient with X-linked lymphoproliferative syndrome treated with intravenous immunoglobulin and interferon-α

AU - Okano, Motohiko

AU - Pirruccello, Samuel Jay

AU - Grierson, Helen L.

AU - Johnson, Donald R.

AU - Thiele, Geoffrey Milton

AU - Purtilo, David T.

PY - 1990/3

Y1 - 1990/3

N2 - We have studied a 19-year-old male with X-linked lymphoproliferative syndrome (XLP) and infectious mononucleosis (IM) who was treated with high-dose immunoglobulin (500 mg/kg/day) and recombinant interferon (IFN)-α (2 × 106 IU/m2/day). Fulminant hepatitis was delayed; however, virus-associated hemophagocytic syndrome, cholestatic jaundice, and renal failure occurred terminally. Initially, nonspecific natural killer (NK) cell activity against K562 cells was normal but it gradually decreased. Although reactive T cells were markedly increased in his blood during the acute phase, spontaneous EBV-positive cell lines were easily established. Additionally, his mononuclear cells produced IFN-γ but not IFN-α prior to treatment. Based on results of in vitro studies, we conclude that both IFN-α and IFN-γ production are likely necessary for inhibiting EBV immortalization in vitro. Both IFN-α and -γ were produced in cultures of B95-8 EBV-infected mononuclear cells from EBV-seropositive healthy individuals. These results suggest that defective EBV-specific cytotoxic T cell activity accompanied with defective or discordant IFN-α and -γ production permitted the development of fatal IM in this patient. Combined treatment with immunoglobulin and IFN-α appeared to be partially effective during the early stage of this disease.

AB - We have studied a 19-year-old male with X-linked lymphoproliferative syndrome (XLP) and infectious mononucleosis (IM) who was treated with high-dose immunoglobulin (500 mg/kg/day) and recombinant interferon (IFN)-α (2 × 106 IU/m2/day). Fulminant hepatitis was delayed; however, virus-associated hemophagocytic syndrome, cholestatic jaundice, and renal failure occurred terminally. Initially, nonspecific natural killer (NK) cell activity against K562 cells was normal but it gradually decreased. Although reactive T cells were markedly increased in his blood during the acute phase, spontaneous EBV-positive cell lines were easily established. Additionally, his mononuclear cells produced IFN-γ but not IFN-α prior to treatment. Based on results of in vitro studies, we conclude that both IFN-α and IFN-γ production are likely necessary for inhibiting EBV immortalization in vitro. Both IFN-α and -γ were produced in cultures of B95-8 EBV-infected mononuclear cells from EBV-seropositive healthy individuals. These results suggest that defective EBV-specific cytotoxic T cell activity accompanied with defective or discordant IFN-α and -γ production permitted the development of fatal IM in this patient. Combined treatment with immunoglobulin and IFN-α appeared to be partially effective during the early stage of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0025350758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025350758&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(90)90054-T

DO - 10.1016/0090-1229(90)90054-T

M3 - Article

C2 - 2302842

AN - SCOPUS:0025350758

VL - 54

SP - 410

EP - 418

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -